ANI Pharmaceuticals' Q3 Adjusted Earnings, Net Revenue Rise; Fiscal 2024 Outlook Lifted

MT Newswires Live11-08

ANI Pharmaceuticals (ANIP) reported Q3 adjusted earnings Friday of $1.34 per diluted share, up from $1.27 a year earlier.

Analysts polled by Capital IQ expected $1.09.

Net revenue for the quarter ended Sept. 30 was $148.3 million, compared with $131.8 million a year earlier.

Analysts polled by Capital IQ expected $144.4 million.

The company said it now expects fiscal 2024 adjusted earnings of $4.90 to $5.05 per diluted share, compared with its previous guidance range of $4.38 to $4.82.

Net revenue for the year is now anticipated in the range of $594 million to $602 million, compared with $540 million to $560 million anticipated previously, it added.

Analysts polled by Capital IQ expect $4.72 in normalized EPS on revenue of $590.3 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481179704?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481179704","market":"us","top_or_hot":-1,"title":"ANI Pharmaceuticals' Q3 Adjusted Earnings, Net Revenue Rise; Fiscal 2024 Outlook Lifted","media":"MT Newswires Live","content":"<html><body><p> ANI Pharmaceuticals (ANIP) reported Q3 adjusted earnings Friday of $1.34 per diluted share, up from $1.27 a year earlier.</p><p>Analysts polled by Capital IQ expected $1.09.</p><p>Net revenue for the quarter ended Sept. 30 was $148.3 million, compared with $131.8 million a year earlier.</p><p>Analysts polled by Capital IQ expected $144.4 million.</p><p>The company said it now expects fiscal 2024 adjusted earnings of $4.90 to $5.05 per diluted share, compared with its previous guidance range of $4.38 to $4.82.</p><p>Net revenue for the year is now anticipated in the range of $594 million to $602 million, compared with $540 million to $560 million anticipated previously, it added.</p><p>Analysts polled by Capital IQ expect $4.72 in normalized EPS on revenue of $590.3 million.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ANI Pharmaceuticals' Q3 Adjusted Earnings, Net Revenue Rise; Fiscal 2024 Outlook Lifted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nANI Pharmaceuticals' Q3 Adjusted Earnings, Net Revenue Rise; Fiscal 2024 Outlook Lifted\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ANI Pharmaceuticals (ANIP) reported Q3 adjusted earnings Friday of $1.34 per diluted share, up from $1.27 a year earlier.Analysts polled by Capital IQ expected $1.09.Net revenue for the quarter ended ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIP","symbol_name":"ANI Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481179704","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481179704","pubTimestamp":1731068405,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ANI Pharmaceuticals  reported Q3 adjusted earnings Friday of $1.34 per diluted share, up from $1.27 a year earlier.Analysts polled by Capital IQ expected $1.09.Net revenue for the quarter ended Sept. 30 was $148.3 million, compared with $131.8 million a year earlier.Analysts polled by Capital IQ expected $144.4 million.The company said it now expects fiscal 2024 adjusted earnings of $4.90 to $5.05 per diluted share, compared with its previous guidance range of $4.38 to $4.82.Net revenue for the year is now anticipated in the range of $594 million to $602 million, compared with $540 million to $560 million anticipated previously, it added.Analysts polled by Capital IQ expect $4.72 in normalized EPS on revenue of $590.3 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ANIP":"ANI Pharmaceuticals, Inc."},"translate_title":"ANI Pharmaceuticals第三季度调整后盈利、净收入增长；2024财年展望上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":1},"content_text":"ANI Pharmaceuticals (ANIP) reported Q3 adjusted earnings Friday of $1.34 per diluted share, up from $1.27 a year earlier.Analysts polled by Capital IQ expected $1.09.Net revenue for the quarter ended Sept. 30 was $148.3 million, compared with $131.8 million a year earlier.Analysts polled by Capital IQ expected $144.4 million.The company said it now expects fiscal 2024 adjusted earnings of $4.90 to $5.05 per diluted share, compared with its previous guidance range of $4.38 to $4.82.Net revenue for the year is now anticipated in the range of $594 million to $602 million, compared with $540 million to $560 million anticipated previously, it added.Analysts polled by Capital IQ expect $4.72 in normalized EPS on revenue of $590.3 million.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481179704"}